Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to evaluate intranasal lorazepam in paediatric status epilepticus. This is a potentially, more effective, safer and cheaper treatment for a common paediatric medical emergency compared to our present first line therapy intramuscular paraldehyde.


Clinical Trial Description

The ideal first line anticonvulsant agent would be one that can be safely and easily given at a primary health care facility. It should be quick acting, have minimal cardiorespiratory side effects and have a relatively prolonged effect and be cheap. No combination of drug or delivery system fully satisfies these criteria. There are no large published studies evaluating intranasal lorazepam in paediatric status epilepticus. Given its favourable pharmacokinetics and potential practical advantages, we wished to assess the efficacy and safety of intranasal delivery of lorazepam compared to intramuscular paraldehyde, our existing first line anticonvulsant agent in the treatment of acute seizures in children. ;


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00116064
Study type Interventional
Source University of Malawi College of Medicine
Contact
Status Completed
Phase Phase 3
Start date July 2004
Completion date June 2005

See also
  Status Clinical Trial Phase
Recruiting NCT03883516 - Improving Emergency Management of Status Epilepticus N/A
Recruiting NCT03378687 - A Clinical Study of Children With Status Epilepticus in China N/A
Recruiting NCT00362141 - Safety and Tolerability Study of Levetiracetam to Treat Patients With Status Epilepticus Phase 2
Recruiting NCT05140265 - De-identified UNMH EEG Corpus Database Creation With Fully De-identified Clinical Information
Active, not recruiting NCT04391569 - Randomized Therapy In Status Epilepticus Phase 3
Recruiting NCT06017973 - The Role of Imaging in the Diagnosis, Management and Prognosis of Possible Non-convulsive Status Epilepticus N/A
Completed NCT06334796 - Artificial Intelligence-powered Virtual Assistant for Emergency Triage in Neurology Early Phase 1
Recruiting NCT05491590 - Patient-reported Outcome After Status Epilepticus
Recruiting NCT04421846 - Study of Pathophysiology of Status Epilepticus and Dysimmune Encephalitis N/A
Completed NCT02958605 - Smartphone Apps for Pediatric Resuscitation N/A
Completed NCT02239380 - Lorazepam for the Treatment of Status Epilepticus or Repetitive Status Epilepticus in Japan Phase 3
Completed NCT01796574 - Ketogenic Diet for Refractory Status Epilepticus N/A
Completed NCT02381977 - Prevalence of Acute Critical Neurological Disease in Children: a Global Epidemiological Assessment N/A
Completed NCT00004297 - Phase III Randomized Study of Diazepam Vs Lorazepam Vs Placebo for Prehospital Treatment of Status Epilepticus Phase 3
Completed NCT03905798 - LORA-PITA IV General Investigation
Recruiting NCT05591508 - Ketogenic Diet for Status Epilepticus in Children Post Cessation of Convulsive Status Epilepticus N/A
Completed NCT00735527 - Nasal Versus Venous Lorazepam for Control of Acute Seizures in Children Phase 3
Terminated NCT00265616 - Treatment of Refractory Status Epilepticus Phase 3
Enrolling by invitation NCT06403150 - The Efficacy and Safety of Levetiracetam Versus Fosphenytoin in Convulsive Status Epilepticus Phase 4
Recruiting NCT05246566 - Assessment of Adults Epidemiological Characteristics of Status Epilepticus in the French West Indies and in French Guiana